1 minute read
Dec. 10, 2021
Reldesemtiv: A Second Generation Troponin Activator
reldesemtiv
second gen. oral troponin activator Ph. III candidate for ALS (300 mg BID) from HTS in muscle assay and reducing BP Journal of Medicinal Chemistry Cytokinetics, South San Francisco, CA
Other molecules you may be interested in
DS96432529
The Daiichi Sankyo CDK8 kinase inhibitor, DS96432529, is intended to be a bone anabolic agent. The molecule shows preclinical efficacy and synergy with alendronate or parathyroid hormone. The discovery program was initiated well before the likely target (CDK8) was identified and provides an interesting retrospective case study for [...]